# Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

> **NCT01151046** · PHASE2 · COMPLETED · sponsor: **Merrimack Pharmaceuticals** · enrollment: 118 (actual)

## Conditions studied

- Her2 Negative Breast Cancer Patients

## Interventions

- **DRUG:** MM-121
- **DRUG:** Placebo
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT01151046
- **Lead sponsor:** Merrimack Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2014-06
- **Final completion:** 2014-09
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2016-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01151046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01151046, "Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01151046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*